Lab No.	: JAD/25-02-2023/SR7338151	**Lab Add.**	: Newtown, Kolkata-700156
Patient Name	: **DEBJANI MITRA**	**Ref Dr.**	: Dr.MEDICAL OFFICER
Age	: 30 Y 2 M 3 D	**Collection Date**	: 25/Feb/2023 09:08AM
Gender	: F	**Report Date**	: 25/Feb/2023 02:48PM

Test Name	Result	Unit	Bio Ref. Interval	Method
SODIUM, BLOOD , *GEL SERUM*				
SODIUM,BLOOD	141.00	mEq/L	132 - 146 mEq/L	ISE INDIRECT
THYROID PANEL (T3, T4, TSH) , *GEL SERUM*				
T3-TOTAL (TRI IODOTHYRONINE)	1.23	ng/ml	0.60-1.81 ng/ml	CLIA
T4-TOTAL (THYROXINE)	9.5	µg/dL	3.2-12.6 µg/dL	CLIA
TSH (THYROID STIMULATING HORMONE)	1.78	µIU/mL	0.55-4.78 µIU/mL	CLIA

Serum TSH levels exhibit a diurnal variation with the peak occurring during the night and the nadir, which approximates to 50% of the peak value, occurring between 1000 and 1600 hours.[1,2]

References:

1. Bugalho MJ, Domingues RS, Pinto AC, Garrao A, Catarino AL, Ferreira T, Limbert E and Sobrinho L. Detection of thyroglobulin mRNA transcripts in peripheral blood of
individuals with and without thyroid glands: evidence for thyroglobulin expression by blood cells. Eur J Endocrinol 2001;145:409-13.

2. Bellantone R, Lombardi CP, Bossola M, Ferrante A,Princi P, Boscherini M et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrence varies according to the histologic type: results of a prospective study. Cancer 2001;92:2273-9.

BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy:

FIRST TRIMESTER: 0.10 – 3.00 µ IU/mL

SECOND TRIMESTER: 0.20 -3.50 µ IU/mL

THIRD TRIMESTER : 0.30 -3.50 µ IU/mL

References:

1. *Erik K. Alexander, Elizabeth N. Pearce, Gregory A. Brent, Rosalind S. Brown, Herbert Chen, Chrysoula Dosiou, William A. Grobman, Peter Laurberg, John H. Lazarus, Susan J. Mandel, Robin P. Peeters, and Scott Sullivan.Thyroid.Mar 2017.315-389.http://doi.org/10.1089/thy.2016.0457*

2. *Kalra S, Agarwal S, Aggarwal R, Ranabir S. Trimester-specific thyroid-stimulating hormone: An indian perspective. Indian J Endocr Metab 2018;22:1-4.*

Test Name	Result	Unit	Bio Ref. Interval	Method
POTASSIUM, BLOOD , *GEL SERUM*				
POTASSIUM,BLOOD	4.00	mEq/L	3.5-5.5 mEq/L	ISE INDIRECT

Lab No. : SR7338151	Name : DEBJANI MITRA	Age/G : 30 Y 2 M 3 D / F	Date : 25-02-2023



Dr NEEPA CHOWDHURY
MBBS MD (Biochemistry)
Consultant Biochemist

Suraksha Diagnostic Private Limited
E-mail: info@surakshanet.com | Website: www.surakshanet.com

Lab No. : SR7338151 **Name : DEBJANI MITRA** **Age/G : 30 Y 2 M 3 D / F** **Date : 25-02-2023**

PDF Attached

GLYCATED HAEMOGLOBIN (HBA1C) , *EDTA WHOLE BLOOD*

GLYCATED HEMOGLOBIN (HBA1C)	5.2	%	***FOR BIOLOGICAL REFERENCE INTERVAL DETAILS , PLEASE REFER TO THE BELOW MENTIONED REMARKS/NOTE WITH ADDITIONAL CLINICAL INFORMATION ***	
HbA1c (IFCC)	34.0	mmol/mol		HPLC

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:
Low risk / Normal / non-diabetic : <5.7% (NGSP) / < 39 mmol/mol (IFCC)
Pre-diabetes/High risk of Diabetes : 5.7%- 6.4% (NGSP) / 39 - < 48 mmol/mol (IFCC)
Diabetics-HbA1c level : >/= 6.5% (NGSP) / > 48 mmol/mol (IFCC)

Analyzer used : Bio-Rad-VARIANT TURBO 2.0
Method : HPLC Cation Exchange

Recommendations for glycemic targets
Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
Ø **For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease . Action suggested >8% as it indicates poor control.**
Ø Some patients may benefit from HbA1c goals that are stringent.
Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B_{12}/ folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.
Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

References:
1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.
2. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

Dr. SUPARBA CHAKRABARTI
MBBS, MD(BIOCHEMISTRY)
Consultant Biochemist

Lab No. : SR7338151 **Name : DEBJANI MITRA** **Age/G : 30 Y 2 M 3 D / F** **Date : 25-02-2023**

CBC WITH PLATELET (THROMBOCYTE) COUNT , *EDTA WHOLE BLOOD*

HEMOGLOBIN	12.8	g/dL	12 - 15	PHOTOMETRIC
WBC	4.7	*10^3/µL	4 - 10	DC detection method
RBC	4.30	*10^6/µL	3.8 - 4.8	DC detection method
PLATELET (THROMBOCYTE) COUNT	182	*10^3/µL	150 - 450*10^3/µL	DC detection method/Microscopy
DIFFERENTIAL COUNT				
NEUTROPHILS	51	%	40 - 80 %	Flowcytometry/Microscopy
LYMPHOCYTES	**41**	%	20 - 40 %	Flowcytometry/Microscopy
MONOCYTES	06	%	2 - 10 %	Flowcytometry/Microscopy
EOSINOPHILS	02	%	1 - 6 %	Flowcytometry/Microscopy
BASOPHILS	00	%	0-0.9%	Flowcytometry/Microscopy
CBC SUBGROUP				
HEMATOCRIT / PCV	39.0	%	36 - 46 %	Calculated
MCV	90.7	fl	83 - 101 fl	Calculated
MCH	29.8	pg	27 - 32 pg	Calculated
MCHC	32.9	gm/dl	31.5-34.5 gm/dl	Calculated
RDW - RED CELL DISTRIBUTION WIDTH	**14.8**	%	11.6-14%	Calculated
PDW-PLATELET DISTRIBUTION WIDTH	27.8	fL	8.3 - 25 fL	Calculated
MPV-MEAN PLATELET VOLUME	12.9		7.5 - 11.5 fl	Calculated

DR. NEHA GUPTA
MD, DNB (Pathology)
Consultant Pathologist

Lab No. : SR7338151 **Name : DEBJANI MITRA** **Age/G : 30 Y 2 M 3 D / F** **Date : 25-02-2023**

ESR (ERYTHROCYTE SEDIMENTATION RATE) , *EDTA WHOLE BLOOD*

1stHour	**29**	mm/hr	0.00 - 20.00 mm/hr	Westergren

URINE ROUTINE ALL, ALL , *URINE*

PHYSICAL EXAMINATION

COLOUR	PALE YELLOW			
APPEARANCE	SLIGHTLY HAZY			

CHEMICAL EXAMINATION

pH	8.0		4.6 - 8.0	Dipstick (triple indicator method)
SPECIFIC GRAVITY	1.015		1.005 - 1.030	Dipstick (ion concentration method)
PROTEIN	NOT DETECTED		NOT DETECTED	Dipstick (protein error of pH indicators)/Manual
GLUCOSE	NOT DETECTED		NOT DETECTED	Dipstick(glucose-oxidase-peroxidase method)/Manual
KETONES (ACETOACETIC ACID, ACETONE)	NOT DETECTED		NOT DETECTED	Dipstick (Legals test)/Manual
BLOOD	NOT DETECTED		NOT DETECTED	Dipstick (pseudoperoxidase reaction)
BILIRUBIN	NEGATIVE		NEGATIVE	Dipstick (azo-diazo reaction)/Manual
UROBILINOGEN	NEGATIVE		NEGATIVE	Dipstick (diazonium ion reaction)/Manual
NITRITE	NEGATIVE		NEGATIVE	Dipstick (Griess test)
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	Dipstick (ester hydrolysis reaction)

MICROSCOPIC EXAMINATION

LEUKOCYTES (PUS CELLS)	0-1	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2-3	/hpf	0-5	Microscopy
RED BLOOD CELLS	NOT DETECTED	/hpf	0-2	Microscopy
CAST	NOT DETECTED		NOT DETECTED	Microscopy
CRYSTALS	NOT DETECTED		NOT DETECTED	Microscopy
BACTERIA	NOT DETECTED		NOT DETECTED	Microscopy
YEAST	NOT DETECTED		NOT DETECTED	Microscopy

Note:

1. All urine samples are checked for adequacy and suitability before examination.
2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
4. Negative nitrite test does not exclude urinary tract infections.
5. Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can occur due to cell lysis.
8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria and/or yeast in the urine.

BLOOD GROUP ABO+RH [GEL METHOD] , *EDTA WHOLE BLOOD*

ABO	AB	Gel Card
RH	POSITIVE	Gel Card

TECHNOLOGY USED: GEL METHOD

ADVANTAGES :

- Gel card allows simultaneous forward and reverse grouping.
- Card is scanned and record is preserved for future reference.
- Allows identification of Bombay blood group.
- Daily quality controls are run allowing accurate monitoring.

Lab No. : SR7338151 **Name : DEBJANI MITRA** **Age/G : 30 Y 2 M 3 D / F** **Date : 25-02-2023**

Historical records check not performed.

Dr. PANKTI PATEL
MBBS , MD (PATHOLOGY)
CONSULTANT PATHOLOGIST

Suraksha Diagnostic Private Limited
E-mail: info@surakshanet.com | Website: www.surakshanet.com

Lab No. : SR7338151 **Name : DEBJANI MITRA** **Age/G : 30 Y 2 M 3 D / F** **Date : 25-02-2023**

***CHLORIDE, BLOOD ,** .				
CHLORIDE,BLOOD	108.00	mEq/L	99-109 mEq/L	ISE INDIRECT
UREA,BLOOD , *GEL SERUM*	**15.0**	mg/dL	19-49 mg/dL	Urease with GLDH
CREATININE, BLOOD	0.64	mg/dL	0.5-1.1 mg/dL	Jaffe, alkaline picrate, kinetic
GLUCOSE, FASTING , *BLOOD, NAF PLASMA*				
GLUCOSE,FASTING	86	mg/dL	Impaired Fasting-100-125 . Diabetes- >= 126. Fasting is defined as no caloric intake for at least 8 hours.	Gluc Oxidase Trinder

In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.

Reference :
ADA Standards of Medical Care in Diabetes – 2020. Diabetes Care Volume 43, Supplement 1.

CALCIUM, BLOOD				
CALCIUM,BLOOD	9.60	mg/dL	8.7-10.4 mg/dL	Arsenazo III
URIC ACID, BLOOD , *GEL SERUM*				
URIC ACID,BLOOD	4.20	mg/dL	2.6-6.0 mg/dL	Uricase/Peroxidase
TOTAL PROTEIN [BLOOD] ALB:GLO RATIO , .				
TOTAL PROTEIN	7.00	g/dL	5.7-8.2 g/dL	BIURET METHOD
ALBUMIN	4.2	g/dL	3.2-4.8 g/dL	BCG Dye Binding
GLOBULIN	2.80	g/dl	1.8-3.2 g/dl	Calculated
AG Ratio	1.50		1.0 - 2.5	Calculated
LIPID PROFILE , *GEL SERUM*				
CHOLESTEROL-TOTAL	171.00	mg/dL	Desirable: < 200 mg/dL Borderline high: 200-239 mg/dL High: > or =240 mg/dL	Enzymatic
TRIGLYCERIDES	123.00	mg/dL	Normal:: < 150, BorderlineHigh::150-199, High:: 200-499, VeryHigh::>500	GPO-Trinder
HDL CHOLESTEROL	42.00	mg/dl	< 40 - Low 40-59- Optimum 60 - High	Elimination/catalase
LDL CHOLESTEROL DIRECT	**120.0**	mg/dL	OPTIMAL : <100 mg/dL, Near optimal/ above optimal : 100-129 mg/dL, Borderline high : 130-159 mg/dL, High : 160-189 mg/dL, Very high : >=190 mg/dL	Elimination / Catalase
VLDL	9	mg/dl	< 40 mg/dl	Calculated
CHOL HDL Ratio	4.1		LOW RISK 3.3-4.4 AVERAGE RISK 4.47-7.1 MODERATE RISK 7.1-11.0 HIGH RISK >11.0	Calculated

Reference: *National Cholesterol Education Program. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).* JAMA. *May 16 2001;285(19):2486-97.*

PHOSPHORUS-INORGANIC, BLOOD , *GEL SERUM*				
PHOSPHORUS-INORGANIC,BLOOD	3.0	mg/dL	2.4-5.1 mg/dL	Phosphomolybdate/UV

Suraksha Diagnostic Private Limited
E-mail: info@surakshanet.com | Website: www.surakshanet.com

Lab No. : SR7338151 **Name : DEBJANI MITRA** **Age/G : 30 Y 2 M 3 D / F** **Date : 25-02-2023**



DR. ANANNYA GHOSH
MBBS, MD (Biochemistry)
Consultant Biochemist

Suraksha Diagnostic Private Limited
E-mail: info@surakshanet.com | Website: www.surakshanet.com

Lab No. : SR7338151 **Name : DEBJANI MITRA** **Age/G : 30 Y 2 M 3 D / F** **Date : 27-02-2023**

DEPARTMENT OF CYTOPATHOLOGY

PAP SMEAR REPORT

Lab No : P - 675/23

Reporting System : The 2014 Bethesda System
Specimen : Conventional Vaginal Pap Smear.

Specimen Adequacy : Satisfactory for evaluation :
A satisfactory squamous component is present.
Obscuring elements : Absent.

General Categorization :
Negative for Intraepithelial Lesion / Malignancy (NILM).

Non-Neoplastic Findings :
Mild inflammation is noted in the background.

INTERPRETATION / RESULTS : Negative for Intraepithelial Lesion / Malignancy (NILM).

Note : Pap smear cytology is a screening procedure. Findings should be correlated with colposcopic/local examination and ancillary findings.
As per current recommendation, women aged 30-65 years should be screened with both the HPV test and the Pap test, called "co-testing," as the preferred strategy. Screening with the Pap test alone every 3 years is still acceptable.

Ancillary Testing – For HPV testing using PCR from the same sample (only in case of LBC) request should come within 15 days from the reporting date.

****Report relates to the item tested only.*

Dr. PANKTI PATEL
MBBS , MD (PATHOLOGY)
CONSULTANT PATHOLOGIST

Suraksha Diagnostic Private Limited
E-mail: info@surakshanet.com | Website: www.surakshanet.com

Suraksha DIAGNOSTICS

Lab No.	: JAD/25-02-2023/SR7338151	**Lab Add.**	:
Patient Name	: **DEBJANI MITRA**	**Ref Dr.**	: Dr.MEDICAL OFFICER
Age	: 30 Y 2 M 3 D	**Collection Date**	:
Gender	: F	**Report Date**	: 25/Feb/2023 05:15PM

E.C.G. REPORT

DATA	
HEART RATE	70 Bpm
PR INTERVAL	116 Ms
QRS DURATION	80 Ms
QT INTERVAL	352 Ms
QTC INTERVAL	383 Ms
AXIS	
P WAVE	36 Degree
QRS WAVE	36 Degree
T WAVE	34 Degree
IMPRESSION :	**Normal sinus rhythm, within normal limits.**

ACRay

Dr. A C RAY
Department of Non-invasive Cardiology

Suraksha Diagnostic Private Limited
E-mail: info@surakshanet.com | Website: www.surakshanet.com

Lab No.	: JAD/25-02-2023/SR7338151	**Lab Add.**	:
Patient Name	: **DEBJANI MITRA**	**Ref Dr.**	: Dr.MEDICAL OFFICER
Age	: 30 Y 2 M 3 D	**Collection Date**	:
Gender	: F	**Report Date**	: 25/Feb/2023 04:02PM

X-RAY REPORT OF CHEST (PA)

FINDINGS :

No active lung parenchymal lesion is seen.

Both the hila are normal in size, density and position.

Mediastinum is in central position. Trachea is in midline.

Domes of diaphragm are smoothly outlined. Position is within normal limits.

Lateral costo-phrenic angles are clear.

The cardio-thoracic ratio is normal.

Bony thorax reveals no definite abnormality.

IMPRESSION :

Normal study.

DR. SUBRATA SANYAL
MBBS (CAL), DMRD (CAL).
CONSULTANT SONOLOGIST AND RADIOLOGIST.

Suraksha Diagnostic Private Limited
E-mail: info@surakshanet.com | Website: www.surakshanet.com

Lab No.	: JAD/25-02-2023/SR7338151	**Lab Add.**	:
Patient Name	: **DEBJANI MITRA**	**Ref Dr.**	: Dr.MEDICAL OFFICER
Age	: 30 Y 2 M 3 D	**Collection Date**	:
Gender	: F	**Report Date**	: 25/Feb/2023 03:26PM

DEPARTMENT OF ULTRASONOGRAPHY

REPORT ON EXAMINATION OF WHOLE ABDOMEN

LIVER

Liver is normal in size (135 mm) with smooth margins. Parenchymal echotexture of both lobes are normal. No focal mass lesion is seen in liver. Intrahepatic biliary radicals are not dilated. Portal vein branches and hepatic veins are normal.

PORTA

Portal vein is normal in caliber measures 9 mm.Common bile duct is not dilated (3 mm). No intraluminal calculus or soft tissue is seen in CBD.

GALL BLADDER

Gall bladder is normal in size, shape. No intraluminal calculus or mass is seen. Gall bladder wall is normal in thickness. No pericholecystic fluid collection noted.

PANCREAS

Pancreas is normal in size, shape and contour. Parenchymal echogenicity is normal and homogeneous. No focal mass or calcification seen. Main pancreatic duct is not dilated. No peripancreatic fluid collection or pseudocyst noted.

SPLEEN

Spleen is normal in size (87 mm), shape, position. Echotexture is normal. No focal lesion is noted. Splenic vein at splenic hilum is normal in caliber. No collateral seen.

KIDNEYS

Both the kidneys are normal in size, shape and position. Surfaces are smooth. Cortical echogenicity and cortical thickness of both kidneys are normal. Cortico-medullary differentiation is maintained. No calculus, mass or hydronephrosis is seen in either kidney.

Right kidney measures : 99 mm. Left kidney measures : 104 mm.

URETERS

Ureters are not dilated.

URINARY BLADDER

Urinary bladder is optimally distended. Wall is normal in thickness. No intraluminal calculus or mass is

seen.

UTERUS

Uterus is anteverted, normal in size, measures 69 mm x 41 mm x 31 mm. Myometrial echotexture is homogeneous. No obvious focal mass is seen in myometrium. Endometrial echo is normal in thickness (5 mm) and seen at midline.

POD is clear.

OVARIES

Both the ovaries are normal in size and echotexture. No focal lesion seen.

Right ovary measures : 34 mm x 10 mm.

Left ovary measures : 25 mm x 14 mm.

ADNEXAE

No abnormal mass seen.

RETROPERITONEUM & PERITONEUM

The aorta and IVC are normal. No enlarged lymphnodes are noted in the retroperitoneum. No free fluid is seen in peritoneum.

IMPRESSION:- Normal study.

Kindly note:-

**** Ultrasound is not the modality of choice to rule out subtle bowel lesion.***

**** Please Intimate us for any typing mistakes and send the report for correction within 7 days.***

** The science of Radiological diagnosis is based on the interpretation of various shadows produced by both the normal and abnormal tissues and are not always conclusive. Further biochemical and radiological investigation & clinical correlation is required to enable the clinician to reach the final diagnosis.*

The report and films are not valid for medico-legal purpose.

Patient Identity not verified

Suraksha Diagnostic Private Limited
E-mail: info@surakshanet.com | Website: www.surakshanet.com

Lab No.	: JAD/25-02-2023/SR7338151	**Lab Add.**	:
Patient Name	: **DEBJANI MITRA**	**Ref Dr.**	: Dr.MEDICAL OFFICER
Age	: 30 Y 2 M 3 D	**Collection Date**	:
Gender	: F	**Report Date**	: 25/Feb/2023 03:26PM



Suraksha Diagnostic Private Limited
E-mail: info@surakshanet.com | Website: www.surakshanet.com

SURAKSHA DIAGNOSTIC, RAJARHAT, KOLKATA. **PATIENT REPORT**

BIO-RAD VARIANT TURBO CDM 5.4 **s/n 15893** **V2TURBO_A1c_2.0**

Patient Data

Sample ID:	C02135093827
Patient ID:	SR7338151
Name:	
Physician:	
Sex:	
DOB:	

Comments:

Analysis Data

Analysis Performed:	25/FEB/2023 14:06:16
Injection Number:	4951U
Run Number:	106
Rack ID:	0007
Tube Number:	3
Report Generated:	25/FEB/2023 14:19:41
Operator ID:	ASIT

Peak Name	NGSP %	Area %	Retention Time (min)	Peak Area
A1a	---	1.0	0.156	16429
A1b	---	0.9	0.213	15480
F	---	0.9	0.263	14204
LA1c	---	1.6	0.389	27187
A1c	5.2	---	0.492	68930
P3	---	3.3	0.778	54404
P4	---	1.2	0.858	19856
Ao	---	86.9	0.993	1431465

Total Area: 1,647,955

HbA1c (NGSP) = 5.2 % HbA1c (IFCC) = 34 mmol/mol